江苏长青农化股份有限公司董事会 江苏长青农化股份有限公司 2023 年度董事会工作报告 2023 年度董事会工作报告 2023 年度，江苏长青农化股份有限公司（以下简称"公司"）董事会严格按照 《公司法》、《证券法》、《深圳证券交易所股票上市规则》等有关法律法规和《公司 章程》、《董事会议事规则》等制度的规定，本着对全体股东负责的态度，紧紧围绕 公司发展大计，恪尽职守、诚实守信、勤勉尽责地履行义务及行使职权，认真贯彻 落实股东大会各项决议，积极有效地开展董事会各项工作，不断规范公司运作，提 升公司治理水平，及时完整的履行了信息披露义务，较好地完成了 2023 年度董事会 工作任务。现将公司董事会 2023 年工作情况汇报如下： 一、2023 年度经营情况 2023 年，国内外经济下行压力较大，农药行业市场需求整体低迷，国际市场面 临较大的去库存压力，出口受阻，国内市场竞争更加激烈，产品价格持续下滑，给 公司的生产经营带来较大挑战。公司在董事会的领导下，认真贯彻落实年初制订的 各项目标任务，重点围绕市场销售、安全生产、腾退搬迁和内部管理开展工作，2023 年度实现营业收入 361,447.77 万元，同比下降 ...

股票代码：002391 股票简称：长青股份 公告编号：2024-016 鉴于公司持续、稳健的盈利能力和良好的财务状况，为积极回报广大投资者， 与所有股东分享公司发展经营成果，公司拟定 2023 年度利润分配预案为：以实 施 2023 年度利润分配方案的股权登记日时，扣除公司回购专户上已回购股份后 的总股本为分配基数，向全体股东每 10 股派发现金股利人民币 2 元（含税），不 派送红股，也不实施资本公积金转增股本。公司本次利润分配预案在母公司可供 股东分配利润范围内。 江苏长青农化股份有限公司 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏长青农化股份有限公司（以下简称"公司"）于 2024 年 4 月 16 日召开 第八届董事会第十次会议和第八届监事会第十次会议，审议通过了《2023 年度 利润分配预案》，现将有关事项公告如下： 一、2023年度利润分配预案的基本情况 经立信会计师事务所（特殊普通合伙）审计，公司 2023 年度公司合并报表 范围内实现归属于上市公司股东的净利润为 73,113,919.75 元，提取法 ...

关于江苏长青农化股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2024]第 ZH10082 号 江苏长青农化股份有限公司全体股东： 我们审计了江苏长青农化股份有限公司(以下简称"长青股 份")2023 年度的财务报表，包括 2023 年 12 月 31 日的合并及母公司 资产负债表、2023 年度合并及母公司利润表、合并及母公司现金流 量表、合并及母公司所有者权益变动表和相关财务报表附注，并于 2024 年 4 月 16 日出具了报告号为信会师报字[2024]第 ZH10080 号的 无保留意见审计报告。 长青股份管理层根据中国证券监督管理委员会《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公 告〔2022〕26 号）和《深圳证券交易所上市公司自律监管指南第 1 号——业务办理》的相关规定编制了后附的 2023 年度非经营性资金 占用及其他关联资金往来情况汇总表（以下简称"汇总表"）。 编制汇总表并确保其真实、准确、完整是长青股份管理层的责任。 我们将汇总表所载信息与我们审计长青股份 2023 年度财务报表时所 审核的会计资料及已审计财务报表中 ...

一、续聘会计师事务所事项的情况说明 立信会计师事务所（特殊普通合伙）（以下简称"立信"）具备从事证券业务 相关审计资格，具有多年为上市公司提供审计服务的经验与能力，已连续多年为 公司提供审计服务。在为公司提供审计服务的工作中，立信遵循相关法律、法规 和政策，遵照独立、客观、公正的执业准则，完成了公司2023年度财务报表和内 部控制审计工作，其出具的各项报告能够客观、公正、公允地反映公司财务情况 和经营结果，较好地履行了审计机构职责，从专业角度维护了公司及股东的合法 权益。 为保持审计工作的连续性，同意续聘立信为公司2024年度财务报表和内部控 制审计机构，聘期一年，审计费用由公司董事会提请股东大会授权公司管理层根 据年度审计工作量及市场价格水平协商确定。 二、续聘会计师事务所的基本信息 （一）机构信息 股票代码：002391 股票简称：长青股份 公告编号：2024-017 江苏长青农化股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏长青农化股份有限公司（以下简称"公司"）于2024年4月16日召开第八 届董事会第十 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥3.61 billion, a decrease of 14.83% compared to ¥4.24 billion in 2022[13]. - Net profit attributable to shareholders was approximately ¥73.11 million, down 72.13% from ¥262.35 million in the previous year[13]. - The basic earnings per share decreased to ¥0.1126, a decline of 72.02% from ¥0.4024 in 2022[13]. - Total revenue for Q1 2023 was approximately CNY 1.02 billion, while Q4 2023 revenue decreased to about CNY 824.85 million, reflecting a decline of 19.3% from Q1[29]. - The net profit attributable to shareholders for Q4 2023 was a loss of approximately CNY 142 million, compared to a profit of CNY 90.41 million in Q1 2023, indicating a significant downturn[29]. - Non-recurring gains and losses totaled approximately CNY -12.68 million for 2023, compared to a gain of CNY 8.41 million in 2022, highlighting a deterioration in financial performance[31]. - The company's total operating cost for 2023 was approximately ¥2.7 billion, with the agricultural chemicals segment accounting for 87.85% of this cost, a 9.02% increase from the previous year[106]. - Financial expenses surged by 133.62% to ¥62,319,820.42, primarily due to increased bank loan interest and reduced foreign exchange gains[115]. - R&D expenses decreased by 13.91% to ¥174,402,822.21, representing 4.83% of total revenue[126]. Assets and Liabilities - The total assets at the end of 2023 were approximately ¥8.05 billion, an increase of 7.71% from ¥7.47 billion at the end of 2022[13]. - The net assets attributable to shareholders decreased slightly by 1.26% to approximately ¥4.58 billion from ¥4.64 billion in 2022[13]. - The total liabilities increased by 22.85% to CNY 346,955.50 million compared to the beginning of the year[71]. - The company's inventory accounted for 20.24% of total assets at the end of 2023, up from 19.07% at the beginning of the year[139]. - Short-term borrowings increased to 1,337,750,693.07 yuan, representing 16.62% of total assets, up from 11.09% at the beginning of the year[139]. Market and Industry Trends - The global pesticide market size grew from $35.575 billion in 2006 to $87.7 billion in 2022, with a compound annual growth rate of approximately 5.80%[26]. - The global agricultural chemical industry is experiencing consolidation, with major players like Syngenta and Bayer controlling over 60% of the market, which may impact competitive dynamics[33]. - The focus of the pesticide industry is shifting towards high-efficiency, low-toxicity, and low-residue new environmentally friendly pesticides, with new formulations like water-dispersible granules and controlled-release agents being rapidly developed and promoted[194]. - China is the world's largest pesticide exporter with 1,775 existing pesticide production enterprises, entering a new round of industry consolidation due to intensified competition and environmental pressures[191]. Production and Innovation - The company produced 30,390 tons of active ingredients in 2023, an increase of 46.51% year-on-year[71]. - The company has successfully introduced 30 new pesticide varieties with independent intellectual property rights, covering over 300 million mu of land, demonstrating its innovation capabilities[60]. - The company is focusing on the development of high-efficiency, low-toxicity, and low-residue new environmental-friendly pesticides as a key trend in the industry[169]. - The company has established multiple standardized production workshops to enhance production capacity and efficiency, ensuring high-quality products at competitive prices[95]. - The company has achieved production yield levels comparable to leading international pesticide companies, maintaining a high gross margin in its main business[97]. Sales and Marketing - Revenue from the pesticide segment was approximately ¥3.52 billion, accounting for 97.39% of total revenue, down 15.57% from ¥4.17 billion in 2022[81]. - Domestic sales reached CNY 170,491.06 million, reflecting a growth of 16.76% year-on-year[71]. - The company is focusing on enhancing its marketing strategies and expanding its international market presence[65]. - The company has a comprehensive marketing network covering all 30 provinces in China, enhancing its sales capabilities[108]. - The top five customers accounted for 44.46% of the total annual sales, indicating a significant reliance on a limited customer base[111]. Research and Development - The company plans to continue investing in R&D to enhance product offerings and maintain competitiveness in the market[84]. - The company’s R&D personnel increased by 6.40% to 366, with a notable rise in master's degree holders by 50.00%[126]. - The company is developing new products such as the "Fluazinam" and "Butyl Potassium," aiming for new profit growth points[123]. - The company is committed to increasing R&D investment to enhance the technological content and added value of pesticide products, aiming for a shift towards high-end product manufacturing[169]. Risks and Challenges - The company is facing risks related to industry competition, capacity expansion, and raw material price fluctuations, which could affect future performance[43]. - The company anticipates capacity expansion risks as new projects come online, which may not align with market demand, potentially affecting sales and profitability[179]. - Raw material price fluctuations pose a risk, as they account for approximately 70% of production costs, impacting the company's profitability despite its strong cost transfer capabilities[179]. - The company faces price competition risks due to the low market concentration in the pesticide industry, which may lead to declining product prices and profit margins[179]. - The company is subject to increasing regulatory pressures regarding environmental protection, which may raise operational costs and affect profitability[182]. Future Plans - The company aims for a revenue target of 4 billion yuan for 2024, representing a 10.67% increase compared to 2023[177]. - The company plans to expand its marketing team and enhance product structure to capture a larger share of the domestic formulation market[177]. - The company will focus on high-efficiency, low-toxicity, and low-residue pesticide research, production, and sales[177]. - The company intends to increase overseas registration of raw materials and formulations to build a global sales network[177]. - The company will prioritize safety management to ensure stable production operations across its facilities[177].

股票代码：002391 股票简称：长青股份 公告编号：2024-012 江苏长青农化股份有限公司 第八届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏长青农化股份有限公司（以下简称"公司"）第八届董事会第十次会议 于 2024 年 4 月 16 日在公司会议室以现场方式召开，会议通知于 2024 年 3 月 25 日以通讯方式发送至公司全体董事、监事和高级管理人员。会议由董事长于国权 先生召集并主持，会议应到董事 7 名，现场参会董事 6 名，独立董事李钟华女士 以通讯方式出席本次会议，公司监事和部分高级管理人员列席了会议。本次会议 的召集、召开程序及出席会议的董事人数符合《公司法》和《公司章程》的规定。 经与会董事认真审议，本次会议以记名投票表决方式通过了以下决议： 一、审议通过了《2023 年度董事会工作报告》 2023 年，公司董事会严格按照法律法规、规范性文件及《公司章程》的规 定，本着对全体股东负责的态度，贯彻落实股东大会各项决议，全体董事恪尽职 守、勤勉尽职。 独立董事龚新海先生、李钟华女士、骆广生先生已向公司董事会 ...

一、监事会会议召开情况： 江苏长青农化股份有限公司 2023 年度监事会工作报告 2023年，江苏长青农化股份有限公司监事会依照《公司法》、《公司章程》 等法律法规有关规定，认真履行监督职责，积极维护全体股东的权益。 2023年度公司监事会共召开了三次会议，召开的情况如下： 2、2023年8月14日召开第八届监事会第七次会议，审议通过了以下议案： 报告期内，公司监事会按照《公司法》、《公司章程》的相关规定，认真开 展了监督工作： 1、公司依法运作情况 1、2023年4月10日召开了第八届监事会第六次会议，审议通过了以下议案： （1）《2022年度监事会工作报告》； （2）《2022年年度报告及其摘要》； （3）《2022年度财务决算报告》； （4）《2022年度利润分配预案》； （5）《2022年度内部控制自我评价报告》； （6）《2022年度募集资金存放与使用情况的专项报告》； （7）《2023年第一季度报告》； （8）《关于继续使用暂时闲置募集资金进行现金管理的议案》； （9）《关于续聘会计师事务所的议案》。 （10）《关于部分募集资金投资项目结项并将节余募集资金永久补充流动资 金的议案》。 （1）审议《 ...

江苏长青农化股份有限公司 未来三年（2024年—2026年）股东回报规划 （2024 年 4 月 16 日第八届董事会第十次会议制订） 江苏长青农化股份有限公司（以下简称"公司"）为了健全和完善利润分配的 决策和监督机制，向股东提供持续、合理、稳定的投资回报，引导投资者树立长期 投资和理性投资理念，根据中国证监会《关于进一步落实上市公司现金分红有关事 项的通知》（证监发[2012]37号）、《上市公司监管指引第3号—上市公司现金分 红》（证监会公告（2023）61号）等相关法律、法规、规范性文件以及《公司章程》 的相关规定，结合公司实际情况，特制订公司《未来三年（2024年—2026年）股东 回报规划》（以下简称"本规划"）。 一、本规划考虑的因素 公司着眼于长远和可持续的发展，在综合考量公司所处行业特点、发展阶段、 自身经营模式、发展规划、盈利能力、资金状况、社会资金成本、外部融资环境等 重要因素，以及平衡股东的合理投资回报和公司长远发展的基础上，建立对投资者 持续、稳定、科学的回报规划与机制，以保证利润分配政策的合理性、连续性和稳 定性。 二、本规划制订的原则 1、本规划的制订应符合相关法律、法规和规范性 ...

Financial Performance - The company's revenue for Q1 2024 was ¥859,885,614.78, a decrease of 15.84% compared to ¥1,021,723,217.16 in the same period last year[18] - Net profit attributable to shareholders was ¥7,903,609.81, down 91.26% from ¥90,412,091.70 year-on-year[18] - Basic earnings per share decreased by 91.20% to ¥0.0122 from ¥0.1387 in the same period last year[18] - Total operating revenue for the first quarter was ¥859,885,614.78, a decrease of 15.8% compared to ¥1,021,723,217.16 in the previous period[41] - The company's net profit for the current period is 7,902,233.59, a significant decrease from 90,806,000.14 in the previous period[43] - Total profit for the current period is 7,497,716.12, compared to 11,404,219.09 in the previous period, reflecting a decline[43] Cash Flow - The net cash flow from operating activities was -¥135,368,776.32, representing a decline of 404.58% compared to -¥26,827,951.45 in the previous year[18] - The net cash flow from operating activities decreased by 404.58% to -135,368,776.32 RMB, primarily due to a reduction in cash received from sales of goods and services[22] - Cash inflow from investment activities totaled ¥387,707,436.70, a decrease of 53.8% from ¥839,285,363.82 in the prior year[31] - Cash outflow from investment activities was ¥636,239,541.01, down 41.0% from ¥1,079,413,672.29 in the previous period[31] - The company reported a net cash flow from investment activities of -¥248,532,104.31, slightly worse than -¥240,128,308.47 in the prior year[31] - The net cash flow from financing activities is 384,620,801.97, an increase from 149,676,724.00 in the previous period[45] - The company reported a net cash outflow of -2,287,519.12, compared to -118,104,172.68 in the previous period[45] Assets and Liabilities - Total assets increased by 6.87% to ¥8,603,884,459.82 from ¥8,050,482,608.58 at the end of the previous year[18] - The total liabilities increased to 2,727,079,753.88 RMB, compared to 1,647,924.48 RMB, indicating a significant rise in financial obligations[25] - Long-term borrowings increased by 63.12% to ¥1,106,869,434.61, attributed to loans for fixed asset projects and long-term working capital[21] - Long-term borrowings increased to ¥1,106,869,434.61 from ¥678,559,932.82, reflecting a significant rise in debt[41] - Total liabilities rose to ¥4,059,141,283.93, compared to ¥3,469,554,960.86 in the previous period, indicating increased financial leverage[41] Investments and Fair Value - The company reported a significant increase of 3679.32% in fair value gains to ¥5,313,779.56, mainly due to the settlement of forward foreign exchange contracts[21] - The company reported a fair value change gain of 5,313,779.56, contrasting with a loss of 148,457.76 in the previous period[43] - The company’s investment income showed a loss of -1,679,239.17, a decline from a gain of 5,098,629.92 in the previous period[43] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,532, with the largest shareholder holding 25.40% of the shares[22] - The company’s total equity decreased to ¥4,544,743,175.89 from ¥4,580,927,647.72, showing a slight decline in shareholder value[41] Other Financial Metrics - The company recorded a net loss of ¥2,344,240.60 from non-recurring gains and losses, primarily due to charitable donations[18] - The company incurred interest expenses of 20,569,574.65, up from 18,707,765.75 in the previous period[43] - The company experienced a credit impairment loss of -5,451,947.26, worsening from -1,530,930.35 in the previous period[43] - The company’s cash and cash equivalents decreased to 387,936,348.37 RMB from 401,678,123.47 RMB, a decline of approximately 3.67%[24] - The inventory balance increased to 1,753,600,956.26 RMB, up from 1,629,224,554.92 RMB, reflecting a growth of about 7.63%[24] - The company’s long-term equity investments decreased slightly to 22,696,100.00 RMB from 24,694,100.00 RMB, a decline of about 8.09%[25] - The company’s income tax expense decreased by 142.27% to -3,919,970.93 RMB, primarily due to a decline in profits[22]

江苏长青农化股份有限公司董事会 关于 2023 年度内部控制自我评价报告 江苏长青农化股份有限公司董事会 关于 2023 年度内部控制自我评价报告 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称 "企业内部控制规范体系"），结合江苏长青农化股份有限公司（以下简称"公司"）内部 控制制度和评价方法，在内部控制日常监督和专项监督的基础上，我们对公司截至 2023 年 12 月 31 日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一、重要声明 公司内部控制的目标：建立和完善符合现代企业管理要求的内部组织架构，形成科学的决 策机制、执行机制和监督机制；建立行之有效的内部控制系统，强化风险管理，保证公司 各项业务活动的正常有序运行；严格遵守国家有关法律法规和行业规章，自觉形成守法经 营、规范运作的经营思想；预防和控制各种错误和弊端的发生，消除隐患，合理保证经营 管理合法合规、资产安全、财务报告及相关信息真实完整，提高经营效率和效果，促进公 司经营目标和发展战略的实现。由于内部控制存在的固有局限性，故仅能为实现上述目标 提供合理保证。此外，由于情况的变化可能导致内部控制变得不恰 ...